Journal of International Psychiatry

[Abstract] Aim: To study the effect of fluvoxamine combined with aripiprazole in treatment of patients with obsessive-compulsive disorder and its effect on cognitive behavior. Methods: 84 cases of obsessive-compulsive disorder were selected from March 2015 to February 2016. They were divided into observation group and control group according to admission order, 42 cases in each group. The control group was treated with fluvoxamine. The observation group was treated with aripiprazole on the basis of the control group. The scores of Hamilton Anxiety Scale (HAMA), Yale Brown Forced Scale (Y-BOCS) and cognitive function were compared before and after treatment. The clinical efficacy and side effects were analyzed. Results: After treatment, the scores of HAMA and Y-BOCS in the observation group were significantly lower than the control group [(4.87 ± 0.42)points, (13.58 ± 1.32)points VS (7.65 ± 0.98)points , (18.32 ± 1.41)points](P <0.05). The total clinical effective rate in the observation group was significantly higher than the control group [90.48% (38/42) vs 66.67% (28/42)] (P <0.05). After treatment, the scores of IQ, memory quotient and short-term memory of the observation group were significantly higher than the control group [(106.71 ± 11.32)points, (104.32 ± 8.97)points, (63.45 ± 6.87)points VS (101.32 ± 8.97)points, (98.54 ± 7.82)points, (59.59 ± 5.81) points] (P <0.05). There was no significant difference in adverse reaction rate between the observation group and the control group [26.19% (11/42) vs 23.81% (10/42)] (P> 0.05). Conclusion: Fluvoxamine combined with aripiprazole can improve the cognitive function and clinical symptoms of patients with obsessive-compulsive disorder. The clinical efficacy is good and the safety is high.

【Key words】 fluvoxamine; aripiprazole; obsessive-compulsive disorder; cognitive function